|
Patrick G. Enright is a founder and Managing Director of Longitude Capital focusing on investments in biotechnology. From 2002 through 2006 Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot he was a Managing Member responsible for the Delta Opportunity Fund where he invested in privately-held and publicly-traded biotechnology companies such as SUGEN Inc. and Cephalon Inc. Mr. Enright began his investment career at PaineWebber Development Corporation a direct investment group focused primarily on biotechnology companies. Mr. Enright also has significant life sciences operations experience. He was CFO and Senior Vice President Business Development of Valentis Inc. (now Urigen Pharmaceuticals Inc.) and Senior Vice President Finance and Business Development of Boehringer Mannheim Pharmaceuticals (now Hoffmann-La Roche). Mr. Enright began his life sciences career 23 years ago at Sandoz (now Novartis). He currently serves on the boards of Corcept and a number of privately-held companies. Mr. Enright holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.S. in Biological Sciences from Stanford University. | 